Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Rhea-AI Summary
Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 1:00 p.m. GMT.
A live webcast will be available via the Investors section of Kyverna's website at ir.kyvernatx.com, and a replay will be posted for approximately 90 days after the conference.
Positive
- None.
Negative
- None.
News Market Reaction – KYTX
In the Nov 10 session, KYTX declined 2.89%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.5% during that session. Argus tracked a trough of -4.3% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Monday, November 17, 2025 at 1:00 p.m. GMT.
A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for approximately 90 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications for the Company to advance into late-stage development. Additionally, its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats, including efficiently expanding into broader autoimmune indications and the potential to increase patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process. For more information, please visit https://kyvernatx.com.
Contacts:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
